Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06666439 · ClinicalTrials.gov registry record
Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer
A clinical trial of Metastatic Invasive Lobular Carcinoma (mILC), sponsored by Julia Foldi.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT06666439 is a study of Metastatic Invasive Lobular Carcinoma (mILC) that is actively recruiting participants, run by Julia Foldi. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06666439, a study of Metastatic Invasive Lobular Carcinoma (mILC), is actively recruiting participants, sponsored by Julia Foldi.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to characterize early dynamic changes in ctDNA, which can aid in tailoring early therapy in patients with metastatic Invasive lobular carcinoma (ILC). Response assessment using ctDNA analysis could not only aid in de-escalation but also escalation strategies.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST circulating tumor DNA (ctDNA)
Study Locations (1)
Pennsylvania
- Magee Women's Hospital of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-12-12 |
| Est. Completion | 2029-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06666439
The ClinicalTrials.gov registry entry for NCT06666439 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Julia Foldi, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Invasive Lobular Carcinoma (mILC) appearing as the primary indexed condition, and to 1 intervention - of which circulating tumor DNA (ctDNA) is the first listed.
NCT06666439 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06666439 about?
NCT06666439 is a clinical study titled "Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer". The goal of this study is to characterize early dynamic changes in ctDNA, which can aid in tailoring early therapy in patients with metastatic Invasive lobular carcinoma (ILC). Response assessment using ctDNA analysis could not only aid in de-escalation but also escalation strategies.
What is the current status of trial NCT06666439?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2024-12-12. Estimated completion is 2029-10-31.
What conditions does trial NCT06666439 study?
This clinical trial studies the following conditions: Metastatic Invasive Lobular Carcinoma (mILC).
What interventions are being tested in trial NCT06666439?
The interventions under investigation include: circulating tumor DNA (ctDNA) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06666439?
This trial is sponsored by Julia Foldi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06666439 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.